Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), marking its first authorized treatment targeting acromegaly, a rare endocrine disorder caused by excessive growth hormone secretion. This once-daily oral medication offers a first-line option for adults not suitable for surgery or with insufficient surgical response. Palsonify competes with existing injectable therapies from Novartis and Ipsen, reflecting a competitive shift in acromegaly management.